On Monday, Shares of salesforce.com, inc. (NYSE:CRM), added 5.91% and closed at $75.10 in the last trading session. The last trading range of the stock ranges between $73.58 and $75.73. The company’s Market capitalization is $51.19 Billion with the total Outstanding Shares of 685.00 million. During the 52-week trading session the minimum price at which share price traded, registered at $52.60 and reached to max level of $84.48. Salesforce [NYSE: CRM], the Customer Success Platform and world’s #1 CRM company, recently declared that Chairman and CEO Marc Benioff will speak at a World Economic Forum event on Monday, October 10, starting at about 4:00 p.m. PT.
Benioff will join United States Secretary of Commerce Penny Pritzker, Kaiser Permanente CEO Bernard Tyson and Chevron Executive Vice President of Midstream and Development Mike Wirth in a panel moderated by World Economic Forum Founder and Executive Chairman Klaus Schwab.
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), jumped 19.33% and closed at $2.84 in the last trading session. The last trading range of the stock ranges between $2.76 and $3.14. The company’s Market capitalization is $76.17 million with the total Outstanding Shares of 25.06 million. During the 52-week trading session the minimum price at which share price traded, registered at $1.41 and reached to max level of $3.19. Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs declared that the Company recently received tentative approval from the U.S. Food and Drug Administration (“FDA”) for the Company’s abbreviated new drug application (“ANDA”) for quetiapine fumarate extended-release tablets in the 50, 150, 200, 300 and 400 mg strengths. The Company’s tentatively-approved product is a generic equivalent for the corresponding strengths of the branded product Seroquel XR® sold in the United States by Astra Zeneca Pharmaceuticals LP (“AstraZeneca”).
Following a settlement agreement between the Company and AstraZeneca dated July 30, 2012, the Company is permitted to launch its generic versions of the 50, 150, 200, 300 and 400 mg strengths of generic Seroquel XR®, on November 1, 2016, subject to FDA final approval of the Company’s ANDA for those strengths. Such FDA final approval is subject to a 180 day exclusivity period regardinga prior filer or filers of a generic equivalent of the branded product. To our knowledge, two companies have first-to-file status and may be in a position to launch on November 1, 2016, although we cannot be certain of that date. Our intent is to launch these strengths after FDA final approval following expiry of the other companies’ exclusivity period(s). There are presently no generics of Seroquel XR® available in the U.S. market as the product is still under Astra Zeneca’s patent protection until November 1, 2017. There can be no assurance that the Company’s quetiapine fumarate extended-release tablets in any of the 50, 150, 200, 300 and 400 mg strengths will receive final FDA approval, or if approved, that they will be successfully commercialized.